Safeplus International Holdings Limited (ACAI) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Safeplus International Holdings Limited (ACAI) trades at $0.001 with AI Score 48/100 (Grade C). Safeplus International Holdings Limited, formerly Biophan Technologies, focuses on developing and marketing medical device technologies. Sector: Financial services.
Price as of Jul 23, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for ACAI: ACAI does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ACAI against Financial Services peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ACAI: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Safeplus International Holdings Limited (ACAI) Financial Services Profile
Safeplus International Holdings Limited, operating in the financial services sector as a shell company, focuses on developing and marketing medical device technologies. The company seeks partnerships to monetize its patented technologies, including biothermal power supply and pulsewidth modulation technology, primarily targeting the medical device industry.
What Is the Investment Thesis for ACAI?
Safeplus International Holdings Limited presents a speculative investment opportunity due to its focus on monetizing patented medical device technologies. The company's success hinges on securing partnerships to commercialize its biothermal power, pulsewidth modulation, photonics, and nanomaterials patents. Key value drivers include the successful licensing or sale of these patents, which could generate significant revenue. However, the company's small size, limited operating history under the Safeplus name, and OTC listing introduce substantial risks. The negative P/E ratio of -0.27 and a beta of -17.91 highlight the company's current financial instability and high volatility. Growth catalysts depend on the company's ability to attract partners and demonstrate the value of its technologies, while risks include the failure to monetize patents and continued operating losses.
Based on FMP financials and quantitative analysis
ACAI Key Highlights
- Market capitalization of $0.00B indicates a micro-cap company with limited financial resources.
- Negative P/E ratio of -0.27 reflects the company's lack of profitability.
- Beta of -17.91 suggests extremely high volatility compared to the overall market.
- Dividend yield of None indicates that the company does not currently distribute profits to shareholders.
- Focus on patented technologies in the medical device industry provides potential for high-margin revenue streams.
Who Are ACAI's Competitors?
ACAI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AVNI Arvana Inc. | $0.04 | +0.00% | $5.52M | 63 |
| NIHL New Infinity Holdings, Ltd. | $0.11 | +25.16% | $12.3M | 62 |
| LRGR Luminar Media Group, Inc. | $0.50 | +47.06% | $22.4M | 68 |
| CLAYU Chavant Capital Acquisition Corp. | $10.97 | +18.34% | $27.5M | 62 |
| CLAY Chavant Capital Acquisition Corp. | $10.66 | +6.39% | $29.6M | 62 |
| HHGC HHG Capital Corporation | $11.12 | +0.09% | $56.2M | 63 |
| MAAQ Mana Capital Acquisition Corp. | $5.99 | -24.18% | $57.0M | 61 |
| RCLFU Rosecliff Acquisition Corp I | $11.33 | +11.74% | $77.2M | 62 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ACAI's Key Strengths?
- Patented technologies in the medical device industry.
- Potential for high-margin revenue streams.
- Focus on niche technologies.
- Experienced leadership.
What Are ACAI's Weaknesses?
- Small size and limited resources.
- Dependence on securing partnerships.
- OTC listing increases risk.
- Negative P/E ratio indicates lack of profitability.
What Could Drive ACAI Stock Higher?
- Securing partnerships to monetize patented technologies.
- Potential licensing agreements for biothermal power supply technology.
- Development of new applications for photonics and nanomaterials patents.
What Are the Key Risks for ACAI?
- Negative return on equity (-58.2%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Failure to secure partnerships or monetize patents.
- Limited financial resources and small size.
- OTC listing increases risk and volatility.
- Technological obsolescence of patented technologies.
- Competition from larger medical device companies.
What Are the Growth Opportunities for ACAI?
- Securing strategic partnerships with medical device manufacturers: The medical device industry is continuously seeking innovative technologies to enhance their product offerings. Safeplus's patented technologies, such as biothermal power supply and pulsewidth modulation, could be attractive to companies looking to improve the performance of pacemakers and neurostimulators. Successful partnerships would provide Safeplus with revenue streams through licensing fees and royalties, potentially leading to significant growth. The timeline for securing such partnerships is uncertain but could materialize within the next 2-3 years.
- Monetizing photonics and nanomaterials patents: Safeplus holds patents in photonics and nanomaterials, which have applications in various medical devices and diagnostic tools. These patents represent a potential source of revenue through licensing agreements or outright sale. The timeline for monetizing these patents could range from 1-5 years, depending on market demand and technological advancements.
- Expanding patent portfolio through research and development: Investing in research and development to expand its patent portfolio could create new revenue streams for Safeplus. By focusing on emerging technologies in the medical device industry, the company can develop innovative solutions that address unmet needs. This could attract further partnerships and licensing opportunities, driving long-term growth. The timeline for developing new patents and commercializing related technologies is typically 3-5 years.
- Acquiring complementary technologies or companies: Safeplus could pursue strategic acquisitions of complementary technologies or companies to expand its product offerings and market reach. This would allow the company to leverage synergies and create a more comprehensive portfolio of medical device technologies. The timeline for identifying and executing acquisitions is variable but could occur within the next 1-3 years.
- Exploring alternative applications for patented technologies: Safeplus could explore alternative applications for its patented technologies beyond the medical device industry. For example, biothermal power supply technology could be adapted for use in wearable devices or remote sensors. This would diversify the company's revenue streams and reduce its reliance on the medical device market. The timeline for exploring and developing alternative applications is uncertain but could yield results within 2-4 years.
What Opportunities Does ACAI Have?
- Growing demand for innovative medical device technologies.
- Potential for licensing agreements and strategic partnerships.
- Expansion into new applications for patented technologies.
- Acquisition of complementary technologies or companies.
What Threats Does ACAI Face?
- Competition from larger medical device companies.
- Failure to secure partnerships or monetize patents.
- Technological obsolescence.
- Regulatory changes in the medical device industry.
What Are ACAI's Competitive Advantages?
- Patented technologies provide a degree of exclusivity.
- Focus on niche technologies in the medical device industry.
- Potential for strong relationships with medical device manufacturers.
What Does ACAI Do?
Safeplus International Holdings Limited, formerly known as Biophan Technologies, Inc., was founded in 1963 and is based in Pittsford, New York. The company underwent a name change in September 2020, signaling a shift in its strategic direction. Safeplus operates within the financial services sector, specifically as a shell company focused on developing and marketing technologies for the medical device industry. Its core business revolves around seeking partners to monetize its portfolio of patented technologies. These technologies include biothermal power supply and pulsewidth modulation technology designed to enhance the performance of pacemakers and neurostimulators. Additionally, the company holds patents in photonics and nanomaterials, further diversifying its technological assets. With a small team of two employees, Safeplus International Holdings Limited concentrates on leveraging its intellectual property to generate revenue through strategic partnerships and licensing agreements within the medical device market.
What Products and Services Does ACAI Offer?
- Develops and markets technologies for the medical device industry.
- Seeks partners to monetize patented technologies.
- Focuses on biothermal power supply technology.
- Develops pulsewidth modulation technology.
- Holds patents in photonics and nanomaterials.
- Aims to enhance the performance of pacemakers and neurostimulators.
How Does ACAI Make Money?
- Monetizes patented technologies through licensing agreements.
- Generates revenue through strategic partnerships.
- Potentially generates revenue through the sale of patents.
What Industry Does ACAI Operate In?
Safeplus International Holdings Limited operates within the financial services sector as a shell company targeting the medical device industry. The medical device market is characterized by rapid technological advancements and stringent regulatory requirements. Companies like Safeplus seek to capitalize on niche technologies and form partnerships with established medical device manufacturers. The competitive landscape includes both large, diversified medical technology companies and smaller, specialized firms. The company's success depends on its ability to differentiate its patented technologies and navigate the complex regulatory environment.
Who Are ACAI's Key Customers?
- Medical device manufacturers seeking innovative technologies.
- Companies interested in licensing patented technologies.
- Potential acquirers of the company's intellectual property.
Company Profile
Safeplus International Holdings Limited operates in the Shell Companies industry within the Financial Services sector. It is headquartered in Pittsford, US. The company is led by CEO Margaret V. Russell. ACAI has traded publicly since 2002.
How Safeplus International Holdings Limited Is Valued
Relative to its peer group, ACAI's quantitative score of 48/100 is below the peer average of 63/100.
ROE -58%Key Financial Metrics
Return on equity for Safeplus International Holdings Limited stands at -58.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -17.7%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching.
F-Score 1/9Financial Health
Safeplus International Holdings Limited's Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
ACAI Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Patented technologies in the medical device industry.
- Potential for high-margin revenue streams.
- Focus on niche technologies.
- Experienced leadership.
Bear Case
- Small size and limited resources.
- Dependence on securing partnerships.
- OTC listing increases risk.
- Negative P/E ratio indicates lack of profitability.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
ACAI Latest News
No recent news available for ACAI.
ACAI Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ACAI.
Price Targets
Wall Street price target analysis for ACAI.
ACAI MoonshotScore
What does this score mean?
The MoonshotScore rates ACAI 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Classification
Industry Shell CompaniesLeadership: Margaret V. Russell
CEO
Margaret V. Russell serves as the CEO of Safeplus International Holdings Limited, managing a small team of two employees. Information regarding her prior experience and educational background is not available. As CEO, she is responsible for guiding the company's strategic direction, securing partnerships, and overseeing the monetization of its patented technologies in the medical device industry. Her leadership is crucial to the company's success in a competitive and rapidly evolving market.
Track Record: Due to the limited information available, it is not possible to assess Margaret V. Russell's track record at Safeplus International Holdings Limited. The company's performance under her leadership will be a key indicator of her effectiveness as CEO. Investors should monitor the company's progress in securing partnerships, generating revenue, and achieving profitability to evaluate her performance.
ACAI OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Safeplus International Holdings Limited may not meet minimum financial standards or reporting requirements for higher tiers like OTCQB or OTCQX. Companies in this tier may have limited financial disclosures, making it more difficult for investors to assess their financial health and operational performance. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation.
- OTC Tier: OTC Other
- Limited financial disclosures increase the risk of investing in ACAI.
- Low liquidity can make it difficult to buy or sell shares.
- Potential for price manipulation due to lack of regulatory oversight.
- Higher risk of fraud compared to companies listed on major exchanges.
- Limited access to information about the company's operations and financial performance.
- Verify the company's registration and legal status.
- Review any available financial statements and disclosures.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before investing.
- Monitor the company's news and announcements for any red flags.
- Company has been in business since 1963.
- Focus on developing patented technologies.
- Seeking partnerships to monetize its intellectual property.
- Company headquarters located in Pittsford, New York.
- Company changed name in 2020.
ACAI Financial Services Stock FAQ
What does the AI Score mean for ACAI?
ACAI holds an AI Score of 48/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Safeplus International Holdings Limited, formerly Biophan Technologies, focuses on developing and marketing medical device technologies. The company seeks partnerships to monetize its patented …
What does Safeplus International Holdings Limited do?
Safeplus International Holdings Limited operates as a shell company within the financial services sector, focusing on the development and marketing of technologies for the medical device industry. The company's primary objective is to monetize its portfolio of patented technologies, which include biothermal power supply, pulsewidth modulation, photonics, and nanomaterials.
What do analysts say about ACAI stock?
Currently, there is no available analyst coverage for Safeplus International Holdings Limited (ACAI). This lack of coverage is typical for companies trading on the OTC Other tier, which often have limited financial disclosures and low trading volume. Investors should conduct their own thorough due diligence and carefully consider the risks before investing in ACAI.
What are the main risks for ACAI?
The main risks for Safeplus International Holdings Limited include its reliance on securing partnerships to monetize its patented technologies. Failure to do so could significantly impact its revenue and profitability. The company's small size and limited financial resources also pose challenges. Additionally, its OTC listing increases risk due to lower liquidity, potential for price manipulation, and limited regulatory oversight.
What are the key factors to evaluate for ACAI?
Safeplus International Holdings Limited (ACAI) holds an AI score of 48/100 (low). Not financial advice.
How frequently does ACAI data refresh on this page?
ACAI's price was last updated on Jul 23, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ACAI's recent stock price performance?
Safeplus International Holdings Limited (ACAI) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Patented technologies in the medical device industry. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ACAI overvalued or undervalued right now?
Safeplus International Holdings Limited (ACAI) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ACAI before investing?
Before investing in Safeplus International Holdings Limited (ACAI), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on the company's financials and operations.
- OTC listing increases risk and uncertainty.
- Lack of analyst coverage.